@entity403 Tregs Response to Sublingual Allergen Specific Immunotherapy in XXXX Depends on the Manifestation of Allergy.

@entity6542 @entity1 @entity483 @entity5419 @entity565 @entity2490 @entity56 @entity1576 @entity403 @entity2024
UNASSIGNED: Over the last decades @entity56 has become a major health problem worldwide. The only specific treatment to date is @entity6542 ( @entity6542 ). Although it was shown that @entity6542 generates allergen-tolerant T cells, detailed mechanism underlying its activity is still unclear and there is no reliable method to monitor its effectiveness. The aim of our study was to evaluate @entity6542 influence on the frequency of @entity403 ( @entity403 ) Tregs in allergic @entity1 with various clinical manifestations. The relative number of @entity403 Tregs in 32 blood samples from allergic @entity1 at baseline and/or after 1 year of @entity6542 was assessed by flow cytometry. In the entire studied group, the percentage of @entity403 Tregs did not increase 1 year after @entity6542 . Nevertheless, the percentage of @entity403 Tregs after @entity6542 significantly increased in @entity1 with @entity1576 ( @entity2024 , @entity565 , and @entity2490 ) coexisting with nonrespiratory manifestations ( @entity5419 and/or @entity483 ), whereas, in @entity1 with @entity1576 only, the percentage of @entity403 Tregs decreased. To the best of our knowledge, this is the first report showing various differential @entity403 Tregs response to @entity6542 in allergic @entity1 . @entity403 Tregs number could be useful in treatment monitoring. Further studies are warranted to confirm these observations.
